Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C loweringCompany remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027New EDIT-401 preclinical data demonstrating durabil…
Story updates
11:07:33 AM UTC
SquawkNews
Editas Medicine received HREC/TGA clearance in Australia to initiate dosing in the Phase 1/2 Strive trial of EDIT-401 for HeFH, with initial safety/tolerability data expected in Q1 2027 and topline Part 1 safety/efficacy later in 2027.Material DetailsContext by AI AnalystThis marks an early clinica…